Eli Lilly and Co (LLY) : Cypress Asset Management Inctx scooped up 377 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 19, 2016. The investment management firm now holds a total of 91,112 shares of Eli Lilly and Co which is valued at $7,314,471.Eli Lilly and Co makes up approximately 1.42% of Cypress Asset Management Inctx’s portfolio.
Other Hedge Funds, Including , Sunnymeath Asset Management added LLY to its portfolio by purchasing 12,760 company shares during the most recent quarter which is valued at $1,024,373. Eli Lilly and Co makes up approx 1.45% of Sunnymeath Asset Management’s portfolio.
Eli Lilly and Co opened for trading at $80.27 and hit $80.52 on the upside on Wednesday, eventually ending the session at $80.28, with a gain of 0.39% or 0.31 points. The heightened volatility saw the trading volume jump to 28,11,087 shares. Company has a market cap of $88,616 M.
On the company’s financial health, Eli Lilly and Co reported $0.83 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Apr 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $4865.10 million for the quarter, compared to analysts expectations of $4829.37 million. The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS.
Investors should note that on Jun 20, 2016, Eli Lilly and Co announced a cash dividend of $0.5100. The company’s management has announced Aug 11, 2016 as the ex-dividend date and fixed the record date on Aug 15, 2016. The payable date has been fixed on Sep 9, 2016.
Many Wall Street Analysts have commented on Eli Lilly and Co. Company shares were Reiterated by Leerink Partners on May 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 101 from a previous price target of $96 .
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.